New York: An advocacy group concerned about costs and possible health problems related to a drug being considered to help stop the spread of HIV infection to healthy people has asked US regulators to delay or deny its approval.
High voter turnout in 5th phase of Lok Sabha polls
FIR against Misa for disturbing poll process
RCB play hard and party hard too: Mallya
Ananth Kumar calls Congress a non-performer across India